19 unchanged sentences
On January 18, 2024, MSN filed a Notice of Appeal to the United States Court of Appeals for the Federal Circuit from the final judgment entered on January 11, 2024.
−Removed: The appeal is fully briefed and awaiting a date for oral argument.
+Added: On June 9, 2025, the Federal Circuit issued a decision affirming the final judgement of the District Court in our favor.
In connection with the Pimavanserin II cases, MSN and Aurobindo are the remaining defendants.
A bench trial was conducted from December 3, 2024 to December 6, 2024 in the matter.
−Removed: Post-trial briefing was completed on February 12, 2025 and we are awaiting the final decision of the Court.
+Added: Post-trial briefing was completed on February 12, 2025.
+Added: On June 9, 2025, the District Court issued a final judgement in our favor that Aurobindo’s ANDA infringes the asserted NUPLAZID patent and that the defendants failed to demonstrate such patent is invalid.
+Added: On June 16, 2025, MSN and Aurobindo filed a Notice of Appeal to the United States Court of Appeals for the Federal Circuit from the final judgment entered on June 9, 2025.
+Added: Briefing was completed on December 19, 2025.
+Added: An oral argument has not been scheduled as yet.
On February 14, 2025, we filed a complaint against Zydus Lifesciences Limited, Zydus Worldwide DMCC, and Zydus Pharmaceuticals (USA) Inc.
(collectively “Zydus”) in the United States District Court for the District of Delaware, alleging infringement of certain of our Orange Book-listed patents covering NUPLAZID (Pimavanserin) by Zydus’ proposed 34 mg pimavanserin tablet product.
−Removed: Zydus has not responded to the complaint as of yet and there is no schedule in place for the case.
+Added: The case is scheduled for trial commencing November 2, 2026.
Securities Class Action
On April 19, 2021, a purported stockholder of us filed a putative securities class action complaint (captioned City of Birmingham Relief Retirement Systems v.
−Removed: Acadia Pharmaceuticals Inc.
+Added: Acadia Pharmaceuticals, Inc., Case No.
21-cv-0762) in the U.S.
−Removed: District Court for the Southern District of California against us and certain of our current executive officers.
+Added: District Court for the Southern District of California against us and certain of our then-current executive officers.
On September 29, 2021, the Court issued an order designating lead plaintiff and lead counsel.
3 unchanged sentences
On March 11, 2024, the Court granted plaintiffs’ motion for class certification and appointment of class representatives and class counsel.
−Removed: The parties are currently engaged in expert discovery, which is scheduled to close on June 13, 2025.
+Added: The parties concluded discovery on September 24, 2025.
+Added: The parties submitted pretrial motions on November 12, 2025 and briefing for these motions will be complete on February 25, 2026.
+Added: The Court has scheduled a pretrial motions hearing for April 10, 2026.
+Added: Remaining pretrial deadlines will be determined pending the Court’s rulings on the parties’ pretrial motions.
Opt-Out Litigation
−Removed: On March 7, 2024, a purported stockholder of the Company filed a complaint (captioned Alger Dynamic Opportunities Fund v.
−Removed: Acadia Pharmaceuticals, Inc.
+Added: On March 7, 2024, a purported stockholder of us filed a complaint (captioned Alger Dynamic Opportunities Fund v.
+Added: Acadia Pharmaceuticals, Inc., Case No.
24-cv-00451) in the U.S.
19 unchanged sentences
The Court granted that request and the action was stayed on February 20, 2024, pending the outcome of our Demand Review Committee’s investigation into the underlying claims.
+Added: The stay was briefly lifted on September 5, 2025 but reinstated on October 17, 2025 and remains in place.
+Added: On January 15, 2026, the parties informed the Court that they had reached a settlement in principle regarding the derivative claims.
+Added: Pursuant to the proposed settlement, which is still subject to Court approval, defendants agreed to certain governance reforms and agreed to an award of $1.5 million in attorneys’ fees to be paid by our insurance carrier.
We currently believe that none of the foregoing claims or other actions pending against us as of December 31, 2025 is likely to have, individually or in the aggregate, a material adverse effect on our business, liquidity, financial position, or results of operations.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.